Updates are available Correction dated 2026-02-16
Click to view Correction: https://doi.org/10.1038/s41467-026-69352-w
-
Authors
Myers, John https://orcid.org/0000-0002-2412-7124
Xiao, Jiayang
Mathura, Raissa K.
Shofty, Ben https://orcid.org/0000-0002-2949-4740
Gates, Victoria
Adkinson, Joshua
Allawala, Anusha B. https://orcid.org/0000-0003-0830-583X
Anand, Adrish https://orcid.org/0000-0002-6673-6251
Gadot, Ron
Najera, Ricardo
Rey, Hernan G.
Mathew, Sanjay J. https://orcid.org/0000-0002-2715-6641
Bijanki, Kelly https://orcid.org/0000-0003-1624-8767
Banks, Garrett https://orcid.org/0000-0001-6292-977X
Watrous, Andrew
Bartoli, Eleonora https://orcid.org/0000-0002-5824-5065
Heilbronner, Sarah R. https://orcid.org/0000-0003-0893-5364
Provenza, Nicole https://orcid.org/0000-0002-6952-5417
Goodman, Wayne K.
Pouratian, Nader https://orcid.org/0000-0002-0426-3241
Hayden, Benjamin Y. https://orcid.org/0000-0002-7678-4281
Sheth, Sameer A. https://orcid.org/0000-0001-8770-8965
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (UH3 NS103549)
- License Information
-
More Information
Article History
Received: 7 September 2024
Accepted: 23 June 2025
First Online: 9 July 2025
Change Date: 16 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-026-69352-w
Competing interests
: Dr. Sheth has received consultant fees or research support from Abbott Laboratories, Boston Scientific, Zimmer Biomet, Koh Young, Neuropace, Varian Medical, Sensoria Therapeutics. He is also co-founder of Motif Neurotech. Dr. Pouratian is a consultant for Abbott Laboratories and Sensoria Therapeutics. Dr. Mathew has received consultant fees or research support from Abbott, Almatica Pharma, Biohaven, BioXcel Therapeutics, Boehringer-Ingelheim, Brii Biosciences, Clexio Biosciences, COMPASS Pathways, Delix Therapeutics, Douglas Pharmaceuticals, Engrail Therapeutics, Freedom Biosciences, Liva Nova, Levo Therapeutics, Merck, Motif Neurotech, Neumora, Neurocrine, Perception Neurosciences, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, Sunovion Pharmaceuticals, Xenon Pharmaceuticals, Worldwide Clinical Trials, and XW Pharma. Dr. Goodman receives royalties from Nview, LLC and OCDscales, LLC. The remaining authors declare no competing interests.
